Search: onr:"swepub:oai:gup.ub.gu.se/99939" >
Multicentre prospec...
Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data.
-
Webb, Nicholas J A (author)
-
Prokurat, Sylwester (author)
-
Vondrak, Karel (author)
-
show more...
-
Watson, Alan R (author)
-
Hughes, David A (author)
-
Marks, Stephen D (author)
-
Moghal, Nadeem E (author)
-
Fitzpatrick, Maggie M (author)
-
Milford, David V (author)
-
Saleem, Moin A (author)
-
Jones, Caroline A (author)
-
- Friman, Styrbjörn, 1948 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery
-
Van Damme-Lombaerts, Rita (author)
-
Janssen, Francoise (author)
-
Hamer, Clare (author)
-
Rhodes, Sarah (author)
-
show less...
-
(creator_code:org_t)
- 2009-01-01
- 2009
- English.
-
In: Pediatric nephrology (Berlin, Germany). - : Springer Science and Business Media LLC. - 0931-041X .- 1432-198X. ; 24:1, s. 177-82
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- A total of 192 children and adolescents undergoing renal transplantation were randomly chosen to receive tacrolimus, azathioprine and corticosteroids (TAS, n = 93) or tacrolimus, azathioprine, corticosteroids and two doses of basiliximab (TAS + B, n = 99). Six-month outcome data have previously been reported; this manuscript reports the 2-year data. Complete 2-year data were available on 164 (85.4%) of the original 192 patients. There was a single death in the TAS arm. Kaplan-Meier estimates of survival free of graft loss at 2 years were 94.9% in the TAS + B arm and 89.6% in the TAS arm [hazard ratio (HR) 0.52; 95% confidence interval (CI) 0.17 to 1.54, P = 0.23]. Estimates of survival free from rejection at 2 years were 75.2% in the TAS + B arm and 68.7% in the TAS arm (HR 0.81; 95% CI 0.46 to 1.40, P = 0.44). The mean estimated glomerular filtration rate (GFR) at 2 years, was 65.8 ml/min per 1.73 m(2) body surface area in the TAS arm and 66.7 ml/min per 1.73 m(2) in the TAS + B arm (P = 0.78). Blood pressure and cholesterol levels were similar in the two arms, and there was no evidence of a difference in the incidence of infection or malignancy. These data provide further evidence of a lack of benefit associated with the addition of basiliximab to a TAS regimen for European paediatric renal transplant recipients at low immunological risk.
Keyword
- Adolescent
- Antibodies
- Monoclonal
- therapeutic use
- Azathioprine
- therapeutic use
- Child
- Drug Therapy
- Combination
- Female
- Glomerular Filtration Rate
- Graft Rejection
- immunology
- prevention & control
- Humans
- Immunosuppression
- Immunosuppressive Agents
- therapeutic use
- Kidney Transplantation
- immunology
- Male
- Prednisolone
- therapeutic use
- Prospective Studies
- Recombinant Fusion Proteins
- therapeutic use
- Tacrolimus
- therapeutic use
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Webb, Nicholas J ...
-
Prokurat, Sylwes ...
-
Vondrak, Karel
-
Watson, Alan R
-
Hughes, David A
-
Marks, Stephen D
-
show more...
-
Moghal, Nadeem E
-
Fitzpatrick, Mag ...
-
Milford, David V
-
Saleem, Moin A
-
Jones, Caroline ...
-
Friman, Styrbjör ...
-
Van Damme-Lombae ...
-
Janssen, Francoi ...
-
Hamer, Clare
-
Rhodes, Sarah
-
show less...
- Articles in the publication
-
Pediatric nephro ...
- By the university
-
University of Gothenburg